Home / Transcripts / Yatharth Hospital & Trauma Care Services Limited (YATHARTH) · August 11, 2026

Yatharth Hospital & Trauma Care Services Limited (YATHARTH) Earnings Call Transcript

August 11, 2026

National Stock Exchange of India IN Health Care Health Care Providers and Services earnings 62 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, ladies and gentlemen, and welcome to the Q1 FY 2027 earnings call for Yatharth Hospital & Trauma Care Services Limited. Just a reminder that every participant line is in listen-only mode, and once the presentation wraps up, you'll have a chance to ask questions. If you require help at any point during this call, please signal an operator by pressing star then zero on your touch-tone phone. Kindly note that this conference is being recorded. I'll now turn the conference over to Mr. Vishal Manchanda. Thank you, and over to you, sir.

Vishal Manchanda analyst
#2

Thank you, Athava. Good morning, everyone. We at Systematix Institutional Equities are glad to have you all join us for the Q1 FY 2027 earnings call of Yatharth Hospital & Trauma Care Services Limited. Joining us today is the company's senior management: Mr. Yatharth Tyagi, whole-time director; Mr. Amit Kumar Singh, Group Chief Executive Officer; Mr. Nitin Gupta, President, Finance and Group Chief Operating Officer; Mr. Pankaj Prabhakar, Group Chief Financial Officer; Mr. Ashutosh Kumar Jha, Group Chief Strategy, M&A, and Investor Relations; and Mr. Sonu Goyal, Group Chief Financial Controller. I'll now pass the call to the Yatharth management for their opening remarks. Over to you, sir.

Yatharth Tyagi executive
#3

Hello there. This is Yatharth Tyagi speaking. Good morning, and thank you for joining the earnings conference call of Yatharth Hospital & Trauma Care Services Limited for the quarter that closed on June 30, 2026. With me on the call today are Mr. Amit Singh, our Group CEO; Mr. Pankaj, Group CFO; Mr. Nitin, Group COO and President, Finance; and Mr. Ashutosh, Group Chief Strategy, M&A, and IR, along with Mr. Sonu Goyal, Group Financial Controller. The earnings presentation is now available on the stock exchanges as well as on our website, and we trust you have had a chance to go through it. I am happy to share that FY 2027 has begun on a strong note. During this quarter, we posted our highest quarterly revenue and profits to date. Even more encouraging, revenue growth hit a record 51% year-on-year, while EBITDA rose 39% year-on-year. These results reflect the growth strategy we have been executing across the last several quarters. Our newer hospitals — Greater Faridabad, New Delhi, Faridabad Sector 20, and Agra — together accounted for 27% of the mix in this quarter. Notably, our acquisition playbook is showing early signs of success. One key highlight: our Faridabad Sector 20 hospital reached EBITDA breakeven in a record span of nine months. That hospital now contributes to a monthly revenue run rate of INR 12 to 13 crore, with an ARPOB nearer to INR 40,000, and the potential to climb to INR 45,000-INR 50,000 going forward.

Yatharth Tyagi executive
#4

At our New Delhi hospital, ARPOB has already reached the INR 50,000 threshold, which places us among NCR's premium hospitals. That facility is presently generating monthly revenue at a run rate of INR 8 crore. Crucially, cash and private insurance patients account for 90% plus of the revenue mix at both of these hospitals. Our Agra hospital, integrated during the last quarter, hit a revenue run rate of INR 9 crore-INR 10 crore and posted a robust 20% plus EBITDA in its first full quarter following integration. Construction at Gurugram is moving forward in line with expectations, and we anticipate the hospital going live by quarter one of the next fiscal, with the potential to reach an ARPOB of INR 50,000+. What our results across these hospitals show is the group's capacity not only to spot and acquire quality assets, but also to integrate them and turn their operations around in a very short span of time. Profitability has likewise improved substantially over the past couple of quarters as operating leverage has kicked in, which is reflected in our adjusted EBITDA margin: excluding the impact of New Delhi and Faridabad Sector 20, it came in at 28.1% this quarter. In recognition of the above performance, the board today approved a maiden interim dividend of 5% of face value for all our shareholders, ensuring that shareholders benefit from the growth and investments being done by the Group.

Yatharth Tyagi executive
#5

A major effort across the whole organization sits behind this execution. To reward our people for that work, we have also approved our first ESOP grant and introduced a new ESOP scheme 2026 aimed at attracting, retaining, and aligning quality talent. For us these are meaningful steps, showing our confidence in the business we are building and a commitment to sharing the value created with both our shareholders and our people. We are additionally working to identify ESG priorities throughout our hospital network, with the goal of building an organization that is more sustainable and future-ready. Strengthening our international collaborations stayed a focus this quarter. To expand our global outreach, we opened the Yatharth Information Center in Uzbekistan, and we have also drawn on our partnerships with healthcare institutions, along with undertaking many OPD initiatives across key markets in Asia, Africa, and Middle East. With the infrastructure built over the last 12 months, our network has grown to 2,555 beds, laying the foundation for record growth this year. Going forward, we remain committed to a roadmap that doubles our bed capacity to a 5,000 beds target over the next few years. The upcoming 250-bedded Gurugram facility, expected to commence operations by Q1 of next fiscal, will further strengthen our positioning in the premium NCR market and add another high-potential platform to the network.

Yatharth Tyagi executive
#6

What we need to do now is get those beds occupied, raise utilization, and let earnings catch up to the capacity we've built. On the whole, we see Yatharth moving into an exciting phase. We keep adding capacity. Both our specialty mix and our payer mix keep getting better, and we have a substantial amount of installed capacity to utilize, which will drive stronger cash generation in the years ahead. With that, I'll hand the call over to our CFO, Pankaj, for further updates.

Pankaj Prabhakar executive
#7

Good morning, everyone. I'll walk you through how we performed financially in the first quarter of 2027 and the main factors that shaped that quarter. The group posted quarterly revenue of INR 3,207 million — the highest we've ever recorded — which is a 51% increase year-over-year and 15% higher quarter-over-quarter. Our three established hospitals in Noida and Jhansi-Orchha together brought in INR 2,862 million, with growth of 22% year-over-year. Occupancy at our existing hospitals came in at roughly 75%, while in-patient volume rose 15% year-over-year. Turning to occupancy across the hospitals as a whole, Noida and Jhansi-Orchha both delivered 90% plus occupancy. Greater Noida Hospital is presently running at 74%, and Noida Extension was at 56%. We anticipate that occupancy at Greater Noida and Noida Extension will climb further over the next quarter. The newer hospitals — Greater Faridabad, New Delhi, Faridabad Sector 20, and Agra — together generated INR 1,067 million of revenue, which works out to 27% of the group's revenue. That change in our revenue mix shows how quickly our newer capacity is scaling up, alongside sustained growth from our established base. ARPOB for the group hit an all-time high of INR 34,758 in quarter one, an increase of 7% year-on-year. Notably, our premium NCR hospitals at Noida Extension and New Delhi surpassed the INR 50,000 ARPOB mark for the first time in quarter one, which strongly signals that our case mix is improving.

Pankaj Prabhakar executive
#8

After that came Greater Noida, posting an ARPOB of INR 43,000. Faridabad Sector 20 was nearing INR 40,000. Greater Faridabad and Noida came in at INR 35,000, while Agra was closer to INR 30,000. A stronger specialty mix across our network is the main driver behind this performance. We keep investing in advanced clinical capabilities and infrastructure, since we believe deeper specialty capabilities are essential to building a differentiated hospital network and to improving the quality of our revenue over time. Oncology already contributes close to 10% of the group's revenue, with just one LINAC machine at Noida Extension Hospital at present. We are in the process of adding another LINAC at our Faridabad Sector 20 hospital soon, and after that at the New Delhi facility, which will meaningfully strengthen oncology's share at the group level in the coming years. As newer hospitals show higher ARPOB levels, we expect a meaningful uplift in the overall group's realization as these facilities continue to scale up. EBITDA for the quarter reached its highest ever at INR 917 million, and PAT stood at INR 454 million. Consolidated EBITDA stood at 23.3%, while the adjusted EBITDA margin, excluding the impact of New Delhi and Faridabad Sector 20, stood at 28.1%.

Pankaj Prabhakar executive
#9

As newer hospitals keep advancing along the profitability curve, Agra is delivering an EBITDA margin of 20% plus, while Faridabad Sector 20 reaches EBITDA breakeven in Q1. We anticipate that our blended EBITDA margin will rise from where it stands now. Depreciation and finance costs have climbed in step with the substantial capacity we added during the past 12 months. Even so, our cash profit — that is PAT plus depreciation — rose sharply, up 32% year-on-year, mainly reflecting a non-cash effect on PAT growth. With the coming Gurugram facility and the brownfield expansion plant at Noida Extension and Greater Noida, our total bed capacity will get to more than 3,200 beds. We stay confident about hitting our goal of 5,000 beds within the next five years. FY 2027 has begun on a strong note, and the early success of our newer facilities gives us confidence that we can sustain this momentum. Thank you for your attention. I would now like to hand the call over to the moderator for the question and answer session. Thank you.

Operator operator
#10

Thanks a lot. At this point we'll move into the question-and-answer portion. If you'd like to pose a question, you can press star and one on your touch-tone phone. Should you want to drop out of the queue, press star and two. We ask that participants use their handsets when asking a question. Ladies and gentlemen, we'll pause briefly while the queue is put together. We ask participants to limit themselves to two questions each. Our first question comes from the line of Surbhi Gupta from Trinetra Asset Managers. Please go ahead.

Surbhi Gupta analyst
#11

Morning, sir. First question from my side: the PPT mentions a target of 5,000 beds by three years, but you just said five years—so is it three or five? And the second part: we have one large cluster, Haryana and Delhi, and the second would be U.P. and M.P. Are we aiming to add any further cluster, another one, or will beds be added only within these clusters?

Yatharth Tyagi executive
#12

I think, yes, without a doubt the plan going forward is to double the number of beds we have. As a matter of fact, the capacity we've announced, which takes in Gurugram plus the brownfield additions at Greater Noida and Noida Extension, already sits above 3,200 beds. From that point, when you consider the 5,000-bed capacity, we believe we'll get there even sooner than the three-year target we announced. That would mainly be in the north, the cluster you referred to, yes. We're also looking at other clusters. One approach we've taken before is that we've typically built a cluster. We haven't pursued standalone, independent assets. We've also captured the advantages by adding assets in that surrounding area, much as we've done here. I think even we believe Gurugram remains a very large cluster for us to explore further. A new cluster, clearly, in the north — we identify, I think, that U.P. has certain cities where a solid cluster could be formed. I think we'd still stay with the areas we know very well, which are the north, the Delhi NCR, and the metro cities in the states where we operate.

Surbhi Gupta analyst
#13

Right, all of these are going to come with higher average bed pay, correct?

Yatharth Tyagi executive
#14

Yes. ARPOB would come in well above the group average. As a matter of fact, the newest hospitals we're building are already hitting an ARPOB of nearly INR 50,000. That's plainly the strategy moving forward as well.

Surbhi Gupta analyst
#15

No. Will it exceed 50k, or will it be mostly 50k?

Yatharth Tyagi executive
#16

Roughly 50,000.

Surbhi Gupta analyst
#17

Alright, that’s just my second question, and I’ll keep it quick. Sir, since we’re focused on improving the payer mix, I think we’re also focused on the international mix. If you could speak about that a bit and what kind of benefit we expect to get from it — if you could quantify that.

Speaker unknown
#18

Yeah. Yes, absolutely, we're focused on ways to enhance the payer mix, and that's why, if you look, there's actually a drop of a few percentage points in occupancy at Noida extension. That's entirely in line with what we expected, since our intention was to limit government business, and that's how we're thinking about it. Yes, where international is concerned, there are various initiatives we're planning. In fact, this quarter, I think we're planning five OPD centers — I mean, information centers — across various countries such as CIS or African countries. We've also stationed our very senior marketing person in the African regions. So I think they've begun to show the trends, and I believe this will support a better payer mix as well as the ARPOB as well.

Yatharth Tyagi executive
#19

The playbook is already on display at the new hospitals as well — both New Delhi Model Town and Faridabad Sector 20. At these facilities, close to 90% of the business comes from cash and private insurance, which lets us show it works. At Faridabad, we're pleased it reached break even well ahead of our target, and the way it got there also involved under 10% government business. So I think the playbook is clearly evident, and it's showing up across all the new hospitals. As volumes at these two hospitals keep growing, meaningful shifts will also become visible in the group-level payer mix.

Surbhi Gupta analyst
#20

Alright, sir, thank you very much.

Operator operator
#21

Thanks. We’ll take the next question from Akshat Mehta at Seven Rivers Holding. The line is yours—please proceed.

Akshat Mehta analyst
#22

Hello, sir. Can you hear me?

Operator operator
#23

Yes, please, go right ahead.

Akshat Mehta analyst
#24

I’ll start with the newer hospitals, Delhi and Faridabad. What we have observed is that over the last two, three quarters, occupancy there has more or less plateaued at a similar level. When can we expect occupancy at those hospitals to rise, and where do things stand with government and insurance empowerments for them?

Yatharth Tyagi executive
#25

I don't believe occupancy has been stagnant at all. It's gone up considerably. The explanation for the figures you're seeing is that occupancy gets measured against a different bed capacity. Previously, not every bed was in operation. At present, we're adding capacity quarter-on-quarter, and that's the base against which occupancy is calculated. Occupancy for IPD volumes is clearly rising. That explains why revenue there is climbing quarter-on-quarter. Regarding empanelment, I think many empanelments have already been finished at these two hospitals. It isn't the case that we're holding out for government empanelments and that alone is why the government business is low. Despite the fact that most government empanelments are already in place with us, we're staying with our playbook of not raising the government payor share at these hospitals. And on specific numbers, if you could tell them about occupancy and the beds counted in Faridabad being different from what we counted last quarter.

Speaker unknown
#26

When you look at Delhi, the census bed count there is 150, and occupancy for this quarter was measured against that, whereas last quarter it was 100 beds. That is exactly the factor affecting the overall percentage in that way. At the same time, at the new Faridabad hospital the census bed figure has gone up from 100 beds to 200 census beds. So overall, what we have done is add 160 new census beds into the occupancy counting for this quarter.

Akshat Mehta analyst
#27

Alright, my second question is about the Delhi hospital as a whole. We launched that facility roughly three, four months prior to the Faridabad hospital. Looking at it now, after nearly a year, sir, that hospital has been somewhat slower than Faridabad when it comes to scaling up and occupancy. What's the plan there to reach breakeven and then expand from that point?

Yatharth Tyagi executive
#28

I'd say the Delhi hospital in Model Town is tracking in line with our guidance. We're pretty pleased with how it's coming along. Actually, the numbers there aren't slow — it's more that Faridabad 20 has done better than we expected. We had thought Faridabad Sector 20 would break even in roughly 12 to 14 months, but it broke even sooner than anticipated, at about nine months. On Delhi, we're holding to our guidance. We expected that hospital to reach break-even in around 15 to 17 months, and it remains on track for that. We're quite happy with how Delhi is progressing. I think we're also quite happy with the ARPOB and the monthly revenue run rate it has achieved. The same strategies we're using in Faridabad are being applied in New Delhi — having one of the most reputed doctors in that area, having star doctors, having strong brand recall and community connect in those areas, with strong visibility within the communities. I think both hospitals are moving along the right track.

Akshat Mehta analyst
#29

All right. If I may squeeze in one more question, sir. Regarding the Agra hospital — now that you're at 90% occupancy, do we have plans to bring the remaining census beds into service too, out of those 250 beds?

Speaker unknown
#30

Right. At the moment, with the 250-bed capacity, our census stands at 110 beds. And we’re making plans at this stage to raise that census bed capacity so we can take full advantage of occupancy in the quarters ahead.

Yatharth Tyagi executive
#31

I believe the census beds at Agra are certainly going to go up, and I think there's certainly a lot of room for headway for the Agra hospital to grow when it comes to the numbers.

Akshat Mehta analyst
#32

Alright, thank you, sir.

Operator operator
#33

Thanks. We’ll take the next question from Nishita at Sapphire Capital. Please go ahead.

Analyst analyst
#34

Yeah, hi. I’d just like to get some clarity on those 3,200 beds we’re aiming for — when exactly are they expected to be up and running?

Yatharth Tyagi executive
#35

The announced capacity is 3,200 beds. By that, we mean it's already in our possession. Just a little construction remains. This covers the 250 beds at Gurugram, going live in quarter one of the new financial year, and it also covers roughly 450 beds from brownfield expansion at the two Noida cluster hospitals, which should go live in about the next 15 months.

Analyst analyst
#36

All right, the Noida cluster is going to be up and running within the coming 15 months.

Yatharth Tyagi executive
#37

Yes. It’ll begin to become operational — out of 450, maybe 200 beds would come earlier, and 250 beds will probably be in 18 to 19 months.

Analyst analyst
#38

All right, got it. That still isn't the case, though. So where do we stand right now on capacity? I believe it's 2,800 — is that correct?

Speaker unknown
#39

So the 2,800 capacity figure takes in the new Gurugram acquisition. Like I mentioned-

Analyst analyst
#40

Alright.

Speaker unknown
#41

That needs to take place in quarter one of the next financial year.

Analyst analyst
#42

Alright, got it. For my next question: we saw fairly solid revenue growth of 15% in Q1 FY 2025. Should we expect that growth to keep going? And what kind of growth might we see across the full year FY 2027?

Yatharth Tyagi executive
#43

Regarding the full year FY 2027, I believe we're on course to hit the guidance we've already provided. When it comes not only to revenue but also to the revenue, EBITDA, and PAT figures we're guiding toward for 2027, I feel we'll stay on track for those. Certain parameters, I think, if things keep ramping up as expected, we should also be exceeding some of our guided targets. The company, I think, is on course to meet our guidance.

Analyst analyst
#44

Okay, so could you go over the guidance again? This is my first time actually joining the call.

Yatharth Tyagi executive
#45

Last year, as I believe we mentioned, our growth was 37% year over year. As is plainly evident this year, that pace will be comfortably exceeded. When it comes to EBITDA as well, I'd say the company is on course for roughly in excess of a 24% EBITDA margin across the whole of FY 2027. I'd say much the same applies to ARPOB growth and to the PAT metrics.

Analyst analyst
#46

Okay, so on ARPOB growth, is it fair to expect something in the neighborhood of 10% to 15%?

Yatharth Tyagi executive
#47

My view is that 9%-10% is the appropriate estimate to use.

Analyst analyst
#48

Alright, I've got it. Thanks a lot.

Operator operator
#49

Thanks. Our following question is from Prinita of RediStock Capital Limited. Go right ahead.

Analyst analyst
#50

Hello, can you hear me?

Operator operator
#51

Yes, please, go right ahead.

Analyst analyst
#52

Could you walk me through how quarterly revenues came about from ARPOB, occupancy, and bed count? When I back-calculate with those three metrics over the past few quarters, the figure I get is higher than the revenue that was reported. I just want to understand whether there's a component I'm leaving out of that calculation.

Speaker unknown
#53

So if you look at roughly this quarter, with an ARPOB of close to INR 35,000, a census bed count of 1,820, and occupancy at 68%, those figures will get you to these numbers. When we work out the ARPOB, it takes in total revenue — both IPD and OPD revenues.

Analyst analyst
#54

Wouldn't you advise against handling it individually for each hospital, and instead suggest just one for the whole hospital chain?

Speaker unknown
#55

I can provide the occupancy rate for every one of the hospitals. If you look at roughly how it breaks out, Greater Noida hospital sits at 74% occupancy. Noida Sector 110 comes in at 91% occupancy. Noida Extension is at 56% occupancy. Faridabad Sector 88 — that's Greater Faridabad — has 63% occupancy. The new Faridabad hospital shows 49% occupancy. Model Town, Delhi is at 29% occupancy. Agra stands at 89% occupancy, and Jhansi is at 91% occupancy. But I want to stress here that census bed capacity has been 1,820, versus 655 in the prior quarter. So that's a rise of 175 beds. Still, as we mentioned, there's ample headroom to raise census bed capacity and build the case up to 2,555 across the existing hospitals.

Analyst analyst
#56

Would you mind also pointing out the ARPOB for each one of those hospitals?

Speaker unknown
#57

Sure, absolutely. So the Greater Noida hospital is at an ARPOB of almost INR 43,000. The Noida Extension Hospital comes in above INR 50,000 for ARPOB. Noida Hospital sits at an ARPOB of INR 35,000. Greater Faridabad Hospital is at INR 35,000 for ARPOB. New Faridabad Hospital has an ARPOB of about INR 40,000. Model Town's ARPOB is right around INR 50,000. Agra is at an ARPOB of INR 27,000. And the Jhansi hospital's ARPOB is close to INR 13,000.

Analyst analyst
#58

All right, so let me make sure I've got this straight. When we work out revenue, it would be better to consider all the hospitals as a group for the ARPOB occupancy and bed count, rather than doing it for each hospital individually. Is that right?

Speaker unknown
#59

Right. So when we work out hospital occupancy and also the overall percentage, the factors feed into that overall occupancy percentage. And using blended ARPOB, we assess performance at the blended level.

Analyst analyst
#60

Okay, that's it. Thank you.

Speaker unknown
#61

I really appreciate it.

Operator operator
#62

Thanks. Our next question is from Ashish T. at UTI. Go ahead, please.

Analyst analyst
#63

Appreciate the chance to address that. If you set aside Model Town and Faridabad, our EBITDA margins come in quite strong at 28%. Including the losses, though, naturally they sit lower. At what point do you see the newer assets settling into line, and when might we begin posting 26%-27% EBITDA margin once more?

Yatharth Tyagi executive
#64

So, regarding those two particular hospitals, as we mentioned, Faridabad Sector 20 has already reached breakeven. However, there's still an EBITDA drag, correct? Since I believe the EBITDA margins at that facility are roughly 4%-5%. Therefore, catching up to, say, a 20% EBITDA margin will take some time. For Model Town, we anticipate breakeven at some point between Q3 and Q4 of this year. That should also lessen the EBITDA drag. From this point on, for both of these hospitals, we're aiming at, let's say, roughly 15 months. After they reach breakeven, EBITDA there could be approximately 15%-20%. Yet at the group level, despite that significantly cutting the drag, we may have new hospitals that keep starting up. Within less than 15 months, Gurgaon will also be operational. I think the EBITDA drag from these two hospitals will move to Gurgaon as well as certain other acquisitions we're making. Still, as we said, these two particular hospitals will be in line within 15 to 18 months following breakeven. At the group level, even with the new additions and the continuing EBITDA drag from all the upcoming new hospitals, we'd still be nearer to 24% EBITDA margins.

Analyst analyst
#65

Right.

Speaker unknown
#66

If you look at the type of results we've delivered and shown at the Agra — when we acquired it and began running that operation, it had a beta percentage of almost 11%. Today we're already getting much closer to roughly 24%, 25%. That shows the sort of performance, and the turnover, that reflects the kind of performance our group is capable of.

Analyst analyst
#67

Clearly, we're bringing new assets on board. Our plan is to double the bed counts to 5,000. Looking at the big picture, as we move forward across the next three to five years, I have a specific question about this panel recommending capping hospital room charges at the level of a three-star hotel. Would such recommendations concern you, and if not, what's your perspective on this? Some color would be very helpful.

Speaker unknown
#68

Yes, sir. This news came to us not long ago, so I believe there is a recommendation regarding the room rent ceiling. Right now, we have no comment. You see, when it comes to price increases, there are multiple reasons and multiple factors behind them. How this whole ecosystem is managed—that matters a great deal. At this point, we would rather not comment on it. As the industry progresses, once we get some frameworks, it will probably be appropriate for us to comment and see then.

Yatharth Tyagi executive
#69

Also, look, this isn't the first occasion that a particular recommendation has come up for discussion. Multiple times previously, there have been instances where the center or certain petitions have urged a review of room rents along with private hospital rates. Up to now, what we've observed is that the government has, in fact, consistently backed private hospital growth. Indeed, for the first time in many years, CGHS's rates were revised as well. So our sense is that historically, the government has always supported the private sector too. I recall periods when even stent rates were capped for particular cardiac procedures, certain implants were capped for particular orthopedic procedures, and certain medicines as well. This hasn't — and likely in the future wouldn't — create a significant impact or anything to worry about. In fact, if some optimization of cost can be achieved, I think hospitals will do it. They have kept doing it and have always done so previously. But yes, moving forward, we'll gain more clarity on this. And once again, it's merely a proposal, and I think there's a long way to go before even close to any certain part of it gets implemented as of yet.

Analyst analyst
#70

That's great. That really helps a lot. Thanks very much.

Operator operator
#71

Thanks. Our following question is from Satyam Kumar of AAA Holdings. Go right ahead.

Satyam Kumar analyst
#72

Hello, and thank you for taking my questions. I have two things I'd like to ask. To start, could you help me get a clearer picture, since I'm seeing that the average length of stay for patients has dropped under four days. My understanding is that this marks the first occasion it has come in below four days. So could you help me understand whether we should expect this to become a new, steady pattern of staying under four days, or how we ought to think about it? Is it a one-off? If you could shed some light on that, I'd appreciate it.

Yatharth Tyagi executive
#73

I think this shows up in the overall strategy, first of all, as the new hospitals are ramping up. In those new hospitals, ALOS is lower than the group ALOS we had earlier. The simple reason is that the share of government patients at these new hospitals is very small. Traditionally, government patients have tended to have higher ALOSes, since they come for critical care and for many medical management procedures. I think this is reflected as the new hospitals ramp up, and it also shows in the higher ARPOB growth at the new hospitals. So I think it reflects that, and going forward as well, I think it should be closer to the ALOS numbers we had this quarter.

Speaker unknown
#74

Also, the shift toward surgical cases at the new hospitals is actually shown by the drop in overall ALOS to under 4 days.

Satyam Kumar analyst
#75

Got it. Beyond that, sir, how do you view competitive intensity specifically at your Delhi Model Town hospital? From what I understand, 50 new beds have been added at Model Town hospital. But more broadly, how are you assessing this competitive intensity, and how do you see your ability to raise rates for procedures — or any new procedures you're adding at that hospital — given that it's still in its ramp-up stage?

Speaker unknown
#76

We’re in the ramp-up stage. In Delhi, where we operate, there are two or three large competitors inside a 10-kilometer radius. Let me put it this way: Delhi’s population shifts within a 2–3 km range. The location we’re in is extremely densely populated, and affluent households are right there. That gives us a major opportunity to build a full tertiary or quaternary care facility. In fact, quite soon we’ll offer the full spectrum of oncology treatment, plus the transplant program. The team is of course still working on this and is continuing to onboard a few prominent doctors across the various specialties. I believe we’re quite confident given how Delhi is developing, and as you said, within 15 to 16 months Delhi will reach operational break-even. The thinking behind Delhi is to elevate it to a completely different level by establishing a full quaternary care center in that region.

Satyam Kumar analyst
#77

Sir, just a few quick housekeeping items from me. Could you give us the payer mix for this quarter?

Yatharth Tyagi executive
#78

Regarding the pay mix, for the entire company this quarter, government pay mix is near 40%. Clearly, as I mentioned, at newer hospitals, it accounts for close to no more than 10% of the government business there.

Satyam Kumar analyst
#79

Sir, did the government share go up? Last quarter, as I recall, insurance and cash each stood at 32/32, which put government at 36, and now you're saying 40. So has the government mix risen?

Yatharth Tyagi executive
#80

We haven't seen any growth in volume. My sense is that the effect comes to 1%-2% from the price revision the government made to CGHS rates not long ago. On account of that, I'd expect roughly a 2% lift, or measured against total revenue from the government business. That said, our volumes keep falling quarter after quarter.

Satyam Kumar analyst
#81

So that explains the drop in ALOS. Got it. All right, sir, one final question if I may fit it in — this will be the last one. I'd like to get a handle on this: PAT margins have taken a serious hit. Is there any one-off item or anything you'd want to call out regarding how we ought to view PAT margins going forward? Because the decline has been steep. I realize we're in a ramp-up phase, but no new hospital went live during this quarter, and yet census beds have been added. How should one think about the PAT margin ahead? Thank you.

Speaker unknown
#82

As you can see, we're bringing new hospitals on board. Right, this year our plan includes adding a Gurgaon hospital. Right, so there's interest cost pressure. That alone will feed through to the PAT margin. That's all. Nothing else is affected. If you look at the guidance we're providing for EBITDA, we're reaching approximately 24%-25% EBITDA margin according to that guidance.

Yatharth Tyagi executive
#83

Right, I believe that's down to some significant CapEx we've undertaken in recent months — specifically the Gurgaon acquisition, where construction is still underway. On top of that, we placed an order not long ago for oncology machines serving both Faridabad and Model Town. Considerable CapEx went out in this quarter, along with some increase in debt since FY 2026. That explains why interest cost came in higher. Looking ahead, this will clearly settle down, and that includes depreciation, which ran quite high in quarter one.

Satyam Kumar analyst
#84

And on top of that, regarding the pressure on margins — or is this the range we should be expecting going forward, at least for the near term?

Yatharth Tyagi executive
#85

My view is that the pressure ought to ease from this point onward, since nobody is planning CapEx at this elevated level for any of the quarters coming up soon.

Satyam Kumar analyst
#86

All right, sir, I hear you. That's crystal clear. I understand. Thanks.

Operator operator
#87

Thanks. Our following question is from Disha Parakh of Sunidhi Securities & Finance Limited. You have the floor.

Disha Parakh analyst
#88

Hi there. Can you hear me okay? Hello.

Operator operator
#89

Yes, please, go right ahead.

Disha Parakh analyst
#90

Sure, I had a couple of things I wanted to ask. Can you give us some insight into when the units that were just acquired should become margin accretive and begin adding positively to overall profitability?

Yatharth Tyagi executive
#91

As far as operational breakeven goes, I believe we've covered that already — Faridabad Sector 20 hit it during this quarter, and the Model Town hospital remains on course to get there sometime between Q3 and Q4 of H2. We've also just noted that 15 to 18 months after breakeven, we do expect these hospitals to reach EBITDA margins of roughly 15%-20%. My view is that EBITDA from these hospitals can only go down from this point, and margins ought to expand further, since even on a technical basis, the Gurgaon hospital won't be live for the rest of this financial year. That's the reason we feel margin pressure should ease from here on.

Disha Parakh analyst
#92

And my second question is separate — we've seen that occupancy at the New Delhi unit has stayed somewhat low. Could you explain the reason behind that? Was it caused by a particular demand generation challenge, or were other operational factors involved?

Yatharth Tyagi executive
#93

I believe this is essentially the same question we addressed before. As we said, occupancy is measured at Model Town based on the bed count, and those census beds went up during this quarter. So technically, occupancy rose as well — it did not fall. That's the first point. The second point is that where guidance is concerned, things are pretty much in line. We're quite pleased with how it's progressing. We're quite pleased with the payer mix and with the high ARPOB. Sector Faridabad 20, of course, has done better than expected and surpassed our expectations. But as far as breakeven goes, Model Town will also be in line in the coming quarter.

Disha Parakh analyst
#94

All right. Thanks very much. That’s all.

Operator operator
#95

Thanks. Our following question is from Vidhi Shah with CRK. Go ahead, Vidhi—are you able to hear me? Since we haven’t gotten a response, we’ll proceed to the next question. Our next question is from Vedant Kabra at AVN Capital. Please go ahead.

Vedant Kabra analyst
#96

Sir, congratulations on a wonderful set of numbers. I just had one question about margins. You've provided breakeven per hospital, but I wanted to understand the picture at the group level. Given that Model Town has guided to breakeven in H2 and the other new hospitals are still ramping, when do you expect consolidated EBITDA margins to convert back to the 28% mark? Is that an FY 2028 exit story?

Yatharth Tyagi executive
#97

I don't believe we've ever issued guidance at the consolidated level calling for EBITDA margins of 28%, because, as we said earlier, we'll keep adding new hospitals. So once New Delhi and Faridabad 20 are contributing meaningfully to EBITDA margins, Gurugram will still be there, and it's going live. Then there are a few more acquisitions that will take place over the coming years. We've always said that for this year, I think what we're targeting for EBITDA margin is upwards of 24%. Going forward, yes, an increase of a percentage point or so over a few years is expected, but a 28% EBITDA margin is not something we're targeting anytime soon, even at the consolidated group level.

Vedant Kabra analyst
#98

Sir, could you quantify the potential operating leverage for us? Take a hospital such as Faridabad Sector 20, which has just reached breakeven — as it moves from today's occupancy up to, say, a mature 70%, about what incremental EBITDA margins do those extra patients bring in?

Yatharth Tyagi executive
#99

So at whatever occupancy level the hospital is operating at present—suppose we take the 70% occupancy figure—the incremental EBITDA would come in at roughly 22%-23% EBITDA.

Vedant Kabra analyst
#100

Understood, sir. Noted, sir. And sir, regarding CapEx, since we now aim to reach 5,000 beds, which new geographies are we considering, and do those geographies also carry higher ARPOB, as the Gurugram branch does?

Yatharth Tyagi executive
#101

So yes, that's essentially the plan going forward: we'll be targeting metro cities and large cities where there's potential to reach an ARPOB of INR 50,000. We're in the process of identifying assets. We believe there's still room in the NCR market and in the cluster where we operate to add further beds there, and also to identify new clusters or new metro and big cities. Take U.P., for instance — it has been performing very well on that front. The capital cities of Rajasthan and Haryana still offer huge potential. Those are the areas for expansion going forward.

Vedant Kabra analyst
#102

Alright, sir. Understood. That covers everything from me. Congratulations again, and best wishes.

Operator operator
#103

Thanks. Our next question is from Anuj Kashyap at A3 Capital. Go ahead, please.

Anuj Kashyap analyst
#104

Hi there. Good morning, everyone. Can you hear me? Hello.

Operator operator
#105

Yes, please, go right ahead.

Anuj Kashyap analyst
#106

Sir, I’d like to ask about the attrition figures for the doctors and the ancillary staff. Do we keep a record of that?

Yatharth Tyagi executive
#107

At the group level, our overall attrition rate comes in at almost 7%. Even when you look at the senior—

Anuj Kashyap analyst
#108

All right, continue.

Yatharth Tyagi executive
#109

When you look at senior doctors specifically, the attrition rate is actually lower than that. Sure, some doctors do move around, particularly inside the NCR — that is happening — but relative to the total headcount at a single hospital unit, the number who leave is quite small. Among senior doctors, attrition isn't even 3%-4%, while across doctors overall it sits at 7%. Incidentally, that figure has dropped considerably for us over the course of a few years, since we now run DNB courses in which, say, even a junior doctor will typically remain at the hospital for three years while completing his degree. Previously we didn't have such programs, so we had plenty of JRs and SRs who were moving constantly. These days, that has helped bring our total doctor attrition down to roughly 7%.

Anuj Kashyap analyst
#110

That works in our favor. Sir, the reason I raised this question is that we've introduced an ESOP option for our senior teams, including the doctors. Sir, what would be the proper approach to retaining the team? In what manner does Yatharth, as an institution, reward its doctors through its own method — is it mainly monetary, or is it ESOPs, or something different? Which of these works for us?

Yatharth Tyagi executive
#111

I'd say ESOPs are definitely one thing we've launched not long ago, and that does assist on this front, since at times a good number of star talent across clinical and non-clinical roles — some of those people already hold ESOPs at other organizations, correct? As of today, at this point in time, it's turned into a necessity rather than a nice-to-have for bringing in and keeping top talent. And it isn't solely about money and ESOPs either. Another thing that helps us hold on to star and clinical doctors is simply the freedom to run their departments and practice as they see fit. There aren't the usual P&L pressures on some of these doctors, which is fairly opposite to other organizations in the regions where we operate. That works in our favor, and we always present ourselves to doctors as a very doctor-friendly organization — which is easier said than done. It means a lot to doctors and clinicians to have the level and the respect they deserve, and in our philosophy it also helps us keep them for a long time.

Anuj Kashyap analyst
#112

Thanks very much, sir. That answer was quite thorough. Wishing you the best going forward, sir. Thank you.

Operator operator
#113

Thanks. Our following question is from Akshaya Shinde of Centrum Broking. Go ahead, please.

Akshaya Shinde analyst
#114

Thanks for taking the question, and well done on a solid Q1. What I want to ask about today is the newer hospitals. Those newer facilities are right now running at an ARPOB of roughly INR 50,000 per patient per month. Given the growing emphasis on international patients and the additional <<inaudible>>, how do you expect ARPOB to develop?

Operator operator
#115

Pardon me for cutting in. Your audio isn’t coming through clearly, so could you kindly switch to a handset?

Akshaya Shinde analyst
#116

Just a moment. Can you hear me now?

Operator operator
#117

No, ma'am.

Akshaya Shinde analyst
#118

Can everyone hear me? Is the audio coming through clearly?

Operator operator
#119

Yes. Yes. Go right ahead.

Akshaya Shinde analyst
#120

All right, regarding the newer hospital — its ARPOB currently sits at roughly INR 40,000 to INR 50,000 — and looking forward, with steps like concentrating on international patient flow and bringing in advanced technologies such as LINAC, how would you expect ARPOB to develop across the coming two to three years?

Yatharth Tyagi executive
#121

Our view is that ARPOB should keep rising by roughly 8%-10% YoY annually. We're right on track for that, and we expect the same for this fiscal year.

Akshaya Shinde analyst
#122

Alright. And on top of that, what levels of EBITDA margin do you anticipate those hospitals reaching by FY 2028 and 2029? The majority of them sit at EBITDA breakeven.

Yatharth Tyagi executive
#123

Sure. My sense is that within 2 years from now, those new hospitals ought to reach EBITDA margins even above 25%, somewhere in the neighborhood of 26% to 27%, much like our mature facilities already do. And given the results we've seen from these new hospitals over the recent quarters, we're fairly confident we can get there. Agra is already near 20% to 23% EBITDA margin, and at that site it would come even sooner than the 2-year figure I just mentioned.

Akshaya Shinde analyst
#124

All right. So that robust expansion from the newer hospital — can we treat it as a fresh baseline and expect it to keep moving forward?

Yatharth Tyagi executive
#125

Yes, there's still plenty of runway for growth, since a substantial occupancy ramp-up is still ahead of us. These hospitals have solid capacity. And every year, we're going to add a minimum of one new hospital. Gurugram will be live very soon. I think we want to keep this momentum going—and still keep delivering on the high KPIs of higher ARPOB and a low government mix for all these new hospitals.

Akshaya Shinde analyst
#126

Got it. And one last thing — for the FY 2028 and 2029 periods, would you like to provide any guidance on revenue growth?

Yatharth Tyagi executive
#127

My view is that this year's revenue growth will clearly exceed what we saw last year, and I'd add that this should hold up in the years that follow as well.

Akshaya Shinde analyst
#128

Got it — thanks a lot. That’s helpful. Best of luck.

Operator operator
#129

Thanks. Our following question is from Prerana Amanna with Equity Research Program. Your line is open.

Prerana Amanna analyst
#130

Yes. Hi there. Can you hear me okay?

Operator operator
#131

Yes, go right ahead.

Prerana Amanna analyst
#132

Yeah. Hi, sir. Congrats on such strong results. My question is this: in the PPT from last quarter, you indicated a goal of hitting 5,000 beds over the coming three years — that is, by FY 2029. Could you confirm that, or will you extend the timeline for getting those beds operational? Will it take five years, or three years, meaning by FY 2029?

Yatharth Tyagi executive
#133

My guess is that it will take under 3 years. Last time, we mentioned around 3 years. As we also said, we'll exceed that goal well before then, since 3,200-bed capacity is already in sight and has already been announced. The rest of the capacity should come through more quickly, I think. In the past, we have consistently completed our planned capacity expansion in less time. It could certainly be under 3 years — probably around 2.5 years, I think, would be a fair estimate.

Prerana Amanna analyst
#134

Okay, wow, that's really impressive. And there's one more thing: will we be seeing any additional acquisitions during this year?

Yatharth Tyagi executive
#135

Discussions are underway regarding a set of assets — solid, high-quality ones with strong potential for good and high ARPOB. Our consistent position has been that geography alone isn't what we're after; we also want to be in the specific cities where we already run facilities. Those are the markets where our capacity tends to be the biggest. When we entered Agra, we picked up the finest infrastructure available there. The Jhansi-Orchha hospital fits the same pattern, and so does NCR. Every acquisition we've made has followed that same playbook. Talks are currently ongoing for capital cities in neighboring states. As we've said before, we aim to bring in a minimum of one new hospital every year. Following that logic, I'd expect one new asset to be added during this financial year.

Prerana Amanna analyst
#136

Alright, thank you very much.

Operator operator
#137

Thanks. Our next question is from Virat Pansuriya at Skyridge Wealth Management. Go ahead, please.

Virat Pansuriya analyst
#138

Hi there. Can you hear me okay?

Operator operator
#139

Yes, go right ahead.

Virat Pansuriya analyst
#140

Right. During the past three years, capital expenditure for each bed has risen from INR 30.7 lakh to, I believe, INR 61.4 lakh. What I'd like to get a handle on is what drove that increase, and what we ought to forecast for CapEx per bed on, say, the upcoming 1,800 beds that you're going to add.

Yatharth Tyagi executive
#141

When it comes to the 1,800 beds we plan to add, my view is that capital expenditure should come in at roughly INR 75 to INR 80 lakh per bed, and that figure covers greenfield, brownfield, and acquisitions. It also takes in some lease-based asset-like models we are currently in discussions about. Why was it much lower in the past? Well, back then some of these hospitals weren't even fully outfitted with high-end oncology machines or all the equipment. They began on a small scale, so capital expenditure at these hospitals ramped up gradually. Even the land for the Noida cluster of hospitals we bought was acquired long ago, when prices were far lower. Today, recent prices in the cities where we operate have risen enormously. If we were to build the same hospital now that we built in the Noida cluster around seven or eight years ago, my estimate is that it would cost us close to this same figure of INR 70 to INR 80 lakh in capital expenditure per bed alone. In Gurugram, we are building, and that works out to almost INR 1 crore of capital expenditure per bed for us. So that, I think, explains it, and clearly the equipment and the higher land prices, along with the scale and size of the hospital today that the brand deserves, are what drive this elevated capital expenditure per bed.

Virat Pansuriya analyst
#142

How would the equity and debt structure be split going forward for the rest of the CapEx we have over the next three years?

Operator operator
#143

My apologies for cutting in, sir. Could I ask that you kindly get back in the queue if you have any follow-up questions? Thank you.

Speaker unknown
#144

I'll give the answer. On that front, I'd like to provide it.

Operator operator
#145

Alright.

Speaker unknown
#146

If you look at it, our books showed debt of roughly INR 210 crore in March, and that has now risen to about INR 300 crore. The reason it went up is mainly that we funded part of the acquisition with debt, around INR 80 crore. The remaining amount, though, came from our internal accruals, and that is what was used for this purpose. Looking ahead, we expect to keep using internal accruals for the acquisition as well as to maintain maintenance as growth CapEx, given what our existing hospitals need.

Yatharth Tyagi executive
#147

On the debt side, we feel pretty comfortable. There's still plenty of headroom for us to take on more debt. At a group level, I'd say roughly 2x trailing last 12 months EBITDA is a level we're comfortable carrying, even looking at the times ahead. I think our internal accruals are sufficient, we've got cash, and we have debt capacity to easily fund the CapEx for the remaining 1,800 beds.

Virat Pansuriya analyst
#148

I appreciate that.

Operator operator
#149

Thanks. Everyone, please keep your questions to one question per participant. I'll say that again: please limit each participant to a single question. Our next question comes from Bhagwat at Prosperity Wealth Management. Go ahead, please.

Analyst analyst
#150

Appreciate the chance to ask. I’ll keep it to one brief question. With the assets from the recent acquisitions now added, what depreciation should we expect for the current year? Should Q1’s figures be the pattern for the rest of the year?

Speaker unknown
#151

Regarding depreciation, sir, I was thinking in the region of INR 28 crore to INR 30 crore, all right? That same pattern should continue. Once we bring the Gurugram facility on board, depreciation will rise slightly at the group level — that is, at the group consolidated level. What we are projecting at present is roughly INR 29 crore each quarter.

Analyst analyst
#152

And that’s something we anticipate will carry on through the remaining 3 quarters of this year?

Speaker unknown
#153

Right. Over the coming 3 quarters, since Gurugram won't be added during this financial year. That lands roughly around March or the first quarter of FY 2028.

Analyst analyst
#154

All right. And regarding that fixed asset of ours, which sits at roughly INR 1,200 crore — that's the depreciation figure we should expect, correct?

Speaker unknown
#155

Which one was that? Would you mind asking me that again?

Analyst analyst
#156

On the balance sheet side, we're carrying roughly INR 1,200 crores in fixed assets once you factor in the acquisitions we've completed recently. So based on that fixed asset base, we'd expect depreciation of approximately INR 29 to INR 30 crore each quarter.

Speaker unknown
#157

Yes. It's 29 to 30 crore rupees each quarter.

Analyst analyst
#158

Alright.

Speaker unknown
#159

That takes into account every one of the newly acquired businesses.

Analyst analyst
#160

All right. And will interest expense stay roughly the same for the year as what we saw in Q1?

Speaker unknown
#161

Looking at it now, our interest cost came in at roughly INR 5 crore for the prior quarter. For this quarter, we've reported about INR 6.6 crore. Right. That level will hold going forward, since we won't be taking on any additional fresh loans.

Analyst analyst
#162

All right, thanks for that.

Speaker unknown
#163

Thank you.

Operator operator
#164

Thanks. We’ll take the final question from Vicky Waghwani at Guardian Capital, who is on the line. Please go ahead.

Vicky Waghwani analyst
#165

Hi sir, congratulations on the great set of numbers. I had two questions. First, could you please share progress on the brownfield expansion in Noida, the extension in Greater Noida, and their timelines, please, if you can reiterate.

Yatharth Tyagi executive
#166

My sense is that construction at Greater Noida is now underway and moving. All of the architectural drawings and maps have received approval. As you're aware, in Delhi NCR we're in the middle of monsoon season at the moment. Rain has caused only a slight delay to the construction work. Once the monsoon period is over, building activity will resume at full pace. Noida extension shows a similar pattern. We're currently reviewing all the final drawings along with the structural layout. Our view, as noted earlier on this call, is that capacity from the brownfield expansion should begin coming online in roughly 15 to 18 months.

Vicky Waghwani analyst
#167

Thanks. And then my second question, sir: other expenses as a share of sales have gone up. Gross margin COGS came down, but other expenses rose. Was there any one-off change in accounting practice?

Speaker unknown
#168

So we're talking about Q1 now. As you can see, our doctor cost went up by 2%. That's the sole change. If you look, quarter-on-quarter there's just a 2% change, and that comes purely from the doctor cost. It's one component of other expense. Yeah.

Vicky Waghwani analyst
#169

You're asking about the specialist charges, is that right?

Speaker unknown
#170

Yes. Those are specialist charges. We haven't generated doctors.

Vicky Waghwani analyst
#171

All right, thanks a lot.

Operator operator
#172

Thanks. We’ll treat that as the final question, and at this point I’d like to pass the conference back to management for closing remarks. Thank you, and I’ll turn it over to you.

Yatharth Tyagi executive
#173

Appreciate all of you for your questions and for joining us on this Yatharth Hospital earnings call. Thank you.

Operator operator
#174

Thank you. That brings this conference to a close on behalf of Systematix Institutional Equities and Yatharth Hospital. We appreciate your participation, and you’re welcome to disconnect your lines at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Yatharth Hospital & Trauma Care Services Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Yatharth Hospital & Trauma Care Services Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.